Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

2.

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

PENPACT-1 (PENTA 9/PACTG 390) Study Team., Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, Harper L, Harrison L, Hughes M, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS.

Lancet Infect Dis. 2011 Apr;11(4):273-83. doi: 10.1016/S1473-3099(10)70313-3.

3.

Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children.

Moorthy A, Kuhn L, Coovadia A, Meyers T, Strehlau R, Sherman G, Tsai WY, Chen YH, Abrams EJ, Persaud D.

Clin Infect Dis. 2011 Feb 15;52(4):514-21. doi: 10.1093/cid/ciq161.

4.

Response to planned treatment interruptions in HIV infection varies across childhood.

Paediatric European Network for Treatment of AIDS..

AIDS. 2010 Jan 16;24(2):231-41. doi: 10.1097/QAD.0b013e328333d343.

PMID:
20010073
5.

PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.

PENTA Steering Committee., Welch S, Sharland M, Lyall EG, Tudor-Williams G, Niehues T, Wintergerst U, Bunupuradah T, Hainaut M, Della Negra M, Pena MJ, Amador JT, Gattinara GC, Compagnucci A, Faye A, Giaquinto C, Gibb DM, Gandhi K, Forcat S, Buckberry K, Harper L, Königs C, Patel D, Bastiaans D.

HIV Med. 2009 Nov;10(10):591-613. doi: 10.1111/j.1468-1293.2009.00759.x.

6.

Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants.

Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, Green H, Galli L, Ramos JT, Giaquinto C, Warszawski J, Levy J; European Infant Collaboration group..

AIDS. 2009 Mar 13;23(5):597-604. doi: 10.1097/QAD.0b013e328326ca37.

PMID:
19194272
7.

Early antiretroviral therapy and mortality among HIV-infected infants.

Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-Philippe P, McIntyre JA; CHER Study Team..

N Engl J Med. 2008 Nov 20;359(21):2233-44. doi: 10.1056/NEJMoa0800971.

8.

Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.

United Kingdom Collaborative HIV Cohort Study., Lee KJ, Dunn D, Gilson R, Porter K, Bansi L, Hill T, Phillips AN, Sabin CA, Schwenk A, Leen C, Delpech V, Anderson J, Gazzard B, Johnson M, Easterbrook P, Walsh J, Fisher M, Orkin C.

AIDS. 2008 Oct 1;22(15):1943-50. doi: 10.1097/QAD.0b013e32830e4cf3.

PMID:
18784458
9.

Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.

Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V, Thobakgale C, McCarthy N, Morris L, Walker BD, Goulder P.

AIDS. 2008 Jul 11;22(11):1333-43. doi: 10.1097/QAD.0b013e32830437df.

PMID:
18580613
10.

Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response.

Zanchetta M, Anselmi A, Vendrame D, Rampon O, Giaquinto C, Mazza A, Accapezzato D, Barnaba V, De Rossi A.

Antivir Ther. 2008;13(1):47-55.

PMID:
18389898
11.

Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care.

Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, Novelli V, Lyall EG, Masters J, Tudor-Williams G, Duong T, Gibb DM; Collaborative HIV Paediatric Study (CHIPS).; National Study of HIV in Pregnancy and Childhood (NSHPC)..

Clin Infect Dis. 2007 Oct 1;45(7):918-24.

12.

High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis.

Mphatswe W, Blanckenberg N, Tudor-Williams G, Prendergast A, Thobakgale C, Mkhwanazi N, McCarthy N, Walker BD, Kiepiela P, Goulder P.

AIDS. 2007 Jun 19;21(10):1253-61.

PMID:
17545701
13.

Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants.

Van der Linden D, Hainaut M, Goetghebuer T, Haelterman E, Schmitz V, Maes P, Peltier A, Levy J.

Pediatr Infect Dis J. 2007 Apr;26(4):359-61.

PMID:
17414406
14.

Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection.

Chiappini E, Galli L, Tovo PA, Gabiano C, Gattinara GC, Guarino A, Badolato R, Giaquinto C, Lisi C, de Martino M; Italian Register for HIV Infection in Children..

AIDS. 2006 Jan 9;20(2):207-15. Erratum in: AIDS. 2006 Aug 22;20(13):1789. Baddato, Raffaele [corrected to Badolato, Raffaele].

PMID:
16511413
15.

Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort.

Berk DR, Falkovitz-Halpern MS, Hill DW, Albin C, Arrieta A, Bork JM, Cohan D, Nilson B, Petru A, Ruiz J, Weintrub PS, Wenman W, Maldonado YA; California Pediatric HIV Study Group..

JAMA. 2005 May 11;293(18):2221-31.

PMID:
15886377
16.

HIV cohort collaborations: proposal for harmonization of data exchange.

Kjaer J, Ledergerber B.

Antivir Ther. 2004 Aug;9(4):631-3.

PMID:
15456095
17.

Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study.

Walker AS, Doerholt K, Sharland M, Gibb DM; Collaborative HIV Paediatric Study (CHIPS) Steering Committee..

AIDS. 2004 Sep 24;18(14):1915-24.

PMID:
15353977
18.

Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome.

Aboulker JP, Babiker A, Chaix ML, Compagnucci A, Darbyshire J, Debré M, Faye A, Giaquinto C, Gibb DM, Harper L, Saïdi Y, Walker AS; Paediatric European Network for Treatment of AIDS..

AIDS. 2004 Jan 23;18(2):237-45.

PMID:
15075541
19.

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, Gu K, Hsu A, Brun S, Sun E.

J Infect Dis. 2004 Jan 1;189(1):51-60.

20.

Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads.

Persaud D, Siberry GK, Ahonkhai A, Kajdas J, Monie D, Hutton N, Watson DC, Quinn TC, Ray SC, Siliciano RF.

J Virol. 2004 Jan;78(2):968-79.

Items per page

Supplemental Content

Support Center